The North America next-generation antibody market is witnessing rapid expansion, driven by advancements in biotechnology, increasing demand for targeted therapies, and rising investments in research and development. Next-generation antibodies—such as antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibody fragments—are transforming treatment approaches for...